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ABSTRACT  
In the past few years several investigations have focused on the role of PI3K/AKT/mTOR pathway and its dereg-
ulations in different cancers. This study aimed to examine genetic polymorphisms of this pathway in bladder can-
cer (BC). In this case-control study, 235 patients with pathologically confirmed bladder cancer and 254 control 
subjects were examined. PIK3CA, AKT1 and mTOR variants were analyzed using polymerase chain reaction-re-
striction fragment length polymorphism (PCR-RFLP). The findings proposed that the PIK3CA rs6443624 SNP 
significantly decreased the risk of BC (OR=0.44, 95 % CI=0.30-0.65, p<0.0001 CA vs CC; OR=0.35, 95 % 
CI=0.16-0.78, p=0.0107, AA vs CC; OR=0.60, 95 % CI=0.46-0.79, p=0.0002, A vs T). The AKT1 rs2498801 
variant is associated with a decreased risk of BC (OR=0.57, 95 % CI=0.39-0.82, p=0.003, AG vs AA; OR=0.74, 
95 % CI=0.56-0.97, p=0.032, G vs A) while, AKT1 rs1130233 polymorphism considerably increased the risk of 
BC (OR=3.70, 95 % CI=2.52-5.43, p<0.0001, GA vs GG; OR=5.81, 95 % CI=1.53-21.97, p=0.010, AA vs GG; 
OR=2.71, 95 % CI=1.98-3.70, p<0.0001, A vs G). Additionally, mTOR rs2295080 variant notably increased the 
risk of BC (OR=2.25, 95 % CI=1.50-3.38, p<0.0001, GT vs GG; OR=4.75, 95 % CI=2.80-8.06, p<0.0001, TT vs 
GG; OR=3.10, 95 % CI=2.34-4.10, p<0.0001, T vs G). None of the other examined polymorphisms (AKT1 
rs1130214, AKT1 rs3730358, mTOR rs1883965) revealed significant association with BC. In conclusion, our find-
ings suggest that PIK3CA rs6443624, AKT1 rs2498801, AKT1 rs1130233, as well mTOR rs2295080 polymorphism 
may be related to bladder cancer development in a sample of Iranian population. Validation of our findings in 
larger sample sizes of different ethnicities would provide evidence on the role of variants of PI3K/AKT/mTOR 
pathway in developing BC. 
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INTRODUCTION 
Cancer is a major global public health 
problem (Siegel et al., 2016). Bladder cancer 
is among the most common types of cancer in 
the world, and a recent study reported 
429,800 new cases diagnosed with bladder 
cancer in the year 2012 and a fatality rate of 
165,100 (Torre et al., 2015). It has been sug-
gested that in addition to environmental risk 
factors such as obesity, smoking, and physical 
inactivity (Burger et al., 2013; Shiels et al., 
2014; Vermeulen et al., 2015), genetic factors 
contribute to bladder cancer development 
(Aben et al., 2002; Giedl et al., 2016; Hua et 
al., 2016; Sankhwar et al., 2016).  
One of the main features of cancer devel-
opment and progression is shifting of metab-
olism balance toward faster and higher energy 
production to support energy demand for 
highly proliferative cancer cells (Massari et 
al., 2016). It has been previously reported that 
many metabolic pathways are changed and 
might be involved in BC tumorigenesis and 
malignancies. Recent efforts have been fo-
cused on identifying these pathways and their 
potential applications as serum specific bio-
markers in early diagnosis (Griffin and 
Shockcor, 2004). The phosphatidylinositol 3-
kinase (PI3K)/AKT/mTOR is involved in 
regulation of several basic cellular mecha-
nisms comprising cell growth, cell survival, 
cell motility, angiogenesis, as well as cell me-
tabolism (Knowles et al., 2009; Courtney et 
al., 2010; Bartholomeusz and Gonzalez-
Angulo, 2012; McCubrey et al., 2012). Re-
cent investigations have revealed that muta-
tions in PIK3CA deliberate sensitivity to AKT 
targeted therapy in bladder cancer by regulat-
ing DUSP1 expression and subsequent 
ERK1/2 dephosphorylation and can poten-
tially serve as a stratifying biomarker for 
treatment (Sathe et al., 2014). 
PI3K has two different subunits which is 
involved in regulation of its activity (p85) and 
its catalytic function (p110) (Guerrero-Zotano 
et al., 2016). PIK3CA gene is located on chro-
mosome 3q26.3 that encodes the p110alpha 
catalytic subunit of phosphoinositide 3-ki-
nases (PI3Ks) (Karakas et al., 2006). PI3Ks 
serve as oncogenes and belong to a conserved 
family of lipid kinases that phosphorylate the 
3’-hydroxyl group of phosphoinositides and 
produce phosphatidylinositol-3,4,5-trisphos-
phate (PIP3), a critical second messenger that 
recruits AKT for activation of growth, prolif-
eration and survival signaling (Cantley, 
2002). It has been proposed that mutations in 
the PIK3CA gene is occurred approximately 
in 15 % of human cancers (Karakas et al., 
2006). mTOR inhibitors for prostate cancer 
patients with TSC1 (tuberous sclerosis com-
plex 1) mutations and concomitant targeting 
of PI3K and MEK represent approaches to 
block PI3K/AKT/mTOR pathway (Carneiro 
et al., 2015). 
The AKT1 gene has been mapped to hu-
man chromosome 14 (14q32) (Staal et al., 
1988). AKT proto-oncogen is a serine/threo-
nine kinase with three isoforms (AKT1, 
AKT2, and AKT3). It is a downstream target 
of the PI3K and plays an important role in 
cancer cell survival, cell cycle entry, and glu-
cose metabolism (Engelman, 2009). Poly-
morphisms of AKT gene has been shown to be 
associated with various cancers including na-
sopharyngeal carcinoma (NPC) (Zhang et al., 
2014), gastric cancer (GC) (Piao et al., 2015), 
and prostate cancer (Chen et al., 2012). 
Korkolopoulou et al. (2012) proposed that 
PIK3CA/AKT1 mutational status could be a 
potential predictive marker for time-to-recur-
rence of bladder urothelial carcinoma. 
The mammalian target of rapamycin 
(mTOR) gene is mapped to chromosome 1 
(1p36.22). mTOR is a serine/threonine kinase 
that functions as a downstream effector of the 
PI3K/AKT signaling pathway. It exists as two 
multiprotein complexes, mTORC1 and 
mTORC2 (Keppler-Noreuil et al., 2016). Hy-
per-activation of the PI3K/AKT/mTOR path-
way results in substantial dysregulation of 
normal cellular functions, which may lead to 
various human cancer development (Yuan 
and Cantley, 2008; Knowles et al., 2009; Platt 
et al., 2009; Porta et al., 2014; Houede and 
Pourquier, 2015; Tan et al., 2015; Yuge et al., 
2015; Guerrero-Zotano et al., 2016).  
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There is little information regarding the 
effects of PI3K/AKT/mTOR pathway poly-
morphisms on bladder cancer (Chen et al., 
2009; Lin et al., 2010). To the best of our 
knowledge there is no data concerning the im-
pact of PI3K/AKT/mTOR polymorphism on 
the risk of developing cancer in the Iranian 
population. Therefore, this case-control study 
was designed to assess the possible associa-
tion between PIK3CA, AKT1 and mTOR pol-
ymorphisms and susceptibility to bladder can-
cer in an Iranian population.  
 
MATERIALS AND METHODS 
Patients 
The current case-control study has been 
done in a population of 235 confirmed blad-
der cancer patients and 254 sex and age 
matched cancer free subjects as the control 
group. Demographic and clinicopathological 
characteristics of bladder cancer patients and 
controls are shown in Table 1. The study pro-
tocol for recruitment was approved by the lo-
cal Ethics Committee of Zahedan University 
of Medical Sciences (IR.ZAUMS.REc.1394. 
325), and informed consent was obtained 
from all patients and healthy individuals.  
 
Genotyping 
Genotyping of the variants was done us-
ing polymerase chain reaction-restriction 
fragment length polymorphism (PCR-RFLP) 
methods. The primers sequences are listed in 
Table 2.  
1 μl genomic DNA (~100 ng/μl), 1 μl 
(10 μM) forward and reverse primers, 10 μl 
2X Prime Taq Premix (Genet Bio, Korea), 
and 7 μl ddH2O were added into a 0.20 ml 
PCR reaction tube. The PCR conditions were, 
initial denaturing step at 95 °C for 5 min fol-
lowed by 30 cycles of denaturation at 95°C 
for 30 s, annealing at appropriate temperature 
(Table 1) for 30 s, extension at 72 °C for 30 s, 
and then a final extension step for 10 min at 
72 °C. Then, 10 μl of PCR product was di-
gested by suitable restriction enzyme (Table 
1) based on the manufacturer’s procedure 
(Figure 1). The digested products were elec-
trophoresed on agarose gel containing 0.5 μg/ 
mL ethidium bromide, visualized on a UV 
transilluminator and photograph was taken 
(Figure 1). For the quality control of genotyp-
ing; approximately, 20 % of the random sam-
ples were blindly regenotyped and the repro-
ducibility was 100 %. 
 
Table 1: Demographic and clinicopathological 
characteristics of bladder cancer patients and 
control subjects 
Factors Bladder 
Cancer  
 
Control  
 
Age, Mean ± SD 
(Years) 
63.4±12.1 62.3±10.7 
Sex (male/female) 193/40 210/42 
Histologic type    
Papillary urothe-
lial carcinoma 
212 (90.2) - 
Others 23 (9.8)   
Stage   
PT2c 5 (2.2) - 
PT3b 11 (4.8) - 
LpT1 69 (29.9)  
PT2a 18 (7.8) - 
PT2b 11 (4.8) - 
pT3a 9 (3.9)  
HpT1 41 (17.7)  
LpTa 48 (20.8)  
HpTa 1 (0.4)  
PT4a 12 (5.2)  
PT4b 1 (0.4)  
Carcinoma in situ 5 (2.2)  
   
Surgical margin    
Yes 14 (6.0) - 
No 221 (94.0) - 
Addiction   
Yes 60 (25.5) 3 (1.4) 
No 175 (74.5) 205 (98.6) 
Any history of 
smoking 
  
Yes 100 (42.6) 10 (4.0) 
No 135 (57.4) 238 (96.0) 
Alcohol drinking   
Yes 9 (3.8) 1 (0.4) 
No 226 (96.2) 248 (99.6) 
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Table 2: The primers used for detection of PI3K/AKT/mTOR polymorphisms 
 
Polymorphism 
 
Primer sequence (5’->3’) 
 
An-
neal-
ing 
(°C) 
Re-
striction 
Enzyme 
Fragment 
(bp)  
PIK3CA 
rs6443624 
C>A  
F:  TAAGATGTGCAGAGTTCGTTGTATG 
R:  TTGCCTTTGTAAATATGCTCCATAATC 
 
53 
 
AluI 
A allele:355 
C allele: 
262+93 
PIK3CA 
rs141178472 
T>C 
F:  CTCAATGATGCTTGGCTCTG 
R:  ATCAAACCCTGTTTGCGTTT 
 
56 
 
EcoRII 
T allele: 383 
C allele: 
233+150 
AKT1 rs2498801 
A>G 
F:  ATAATATGGAACCTTCCCTCCAA 
R:  GTCTGTCTCATTCACTGCCCTAC 
 
 
62 
 
BspMI 
A allele: 459 
G allele: 
288+171 
AKT1 rs1130233 
A>G 
F:  CTGCTGTGGGGTGACTTGTTC 
R:  AGGTAGTCCAGGGCTGACACA 
 
68 
 
HpycH4I
V 
G allele: 272  
A allele: 
208+64 
AKT1 rs1130214 
G>T 
F:  GTGCTCCTCACTGACGGACTT 
R:  AGCCTCCCTAACCTGATGCAC 
 
64 
 
XcmI 
T allele: 456 
G allele: 
289+167 
AKT1 rs3730358 
C/T 
F:  AACAACTTCTCTGTGGCGCG-
TAAGTATCCCCTAGGC 
R:  GCCTTAGGACTCAGCCTGGA 
 
66 
 
StuI 
T allele: 259 
C allele: 
224+35 
mTOR 
rs1883965 
G>A 
F:  ATGTACCCCAACGATGTAACCA  
R:  CGGCGTAATGTCCAGACCCA 
 
61 
 
BfaI 
G allele: 412 
A allele: 
310+102 
mTOR 
rs2295080 
G/T 
F:  GCCGTGGGTCTGGACATTAC 
R:  TATTTGAACAGTCCCCGCCC 
 
68 
 
FokI 
G allele: 300 
T allele: 
170+130 
 
 
Statistical analysis 
All statistical analyses were done using 
statistical package SPSS 22 software. The cat-
egorical and continuous variables were exam-
ined using χ2 and t-test, respectively. The as-
sociation between genotypes and BC were 
evaluated by computing the odds ratio (OR) 
and 95 % confidence intervals (95 % CI) from 
non-conditional logistic regression analyses. 
The p-values less than 0.05 were considered 
as statistically significant.  
RESULTS  
The study group consisted of 235 bladder 
cancer patients (193 males, 40 females; age 
63.4 ± 12.1 years) and 255 cancer free sub-
jects as control (210 males, 42 females; age 
62.3 ± 10.7 years). No significant difference 
was observed between the groups regarding 
sex and age (p=0.904 and p=0.316, respec-
tively).  
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Figure 1: Photograph of electrophoresis pattern of the PCR-RFLP method for detection of PIK3CA 
rs6443624 (A), PIK3CA rs141178472 (B), AKT1 rs2498801 (C), AKT1 rs1130233 (D), AKT1 rs1130214 
(E), AKT1 rs3730358 (F), mTOR rs1883965 (G), and mTOR rs2295080 (H). M: DNA marker. For 
PIK3CA rs6443624, lanes 1, 4, and 7: CA; lanes 2, 5, and 8: CC; lanes 3, and 6: AA. For PIK3CA 
rs141178472, all lanes are TT. For AKT1 rs2498801, lanes 1, and 4: AG; lanes 2, and 5: GG; lanes 3, 
and 6: AA. Regarding AKT1 rs1130233, lanes 1, 4, and 6: GA; lanes 1, 5, and 8: GG; lanes 3, and 6: 
AA. For AKT1 rs1130214, lanes 1, 4 and 7: TG; lanes 2, 5, and 8: GG; lanes 3, and 6: TT. For AKT1 
rs3730358, lanes 1, 4, 6, and 7: TC; lanes 2, 5, and 8: CC; lane 3: TT. For mTOR rs1883965, lanes 1, 
4, and 7: AG; lanes 2, 5, and 8: GG; lanes 3, and 6: AA. For mTOR rs2295080, lanes 1, 4, and 7: TG; 
lanes 2, 5, and 8: GG; lanes 3, and 6: TT. 
 
 
 
 
EXCLI Journal 2018;17:3-13 – ISSN 1611-2156 
Received: April 04, 2017, accepted: December 14, 2017, published: January 02, 2018 
 
 
8 
The genotype and allele frequencies of 
polymorphism in bladder cancer patients and 
control group are shown in Table 3. The find-
ings proposed that the PIK3CA rs6443624 
SNP significantly decreased the risk of BC 
(OR=0.44, 95 % CI=0.30-0.65, p<0.0001 CA 
vs CC; OR=0.35, 95 % CI=0.16-0.78, 
p=0.0107, AA vs CC; OR=0.60, 95 % 
CI=0.46-0.79, p=0.0002, A vs T). The AKT1 
rs2498801 variant is associated with a lower 
risk of BC (OR=0.57, 95 % CI=0.39-0.82, 
p=0.003, AG vs AA; OR=0.74, 95 % 
CI=0.56-0.97, p=0.032, G vs A). While, 
AKT1 rs1130233 polymorphism significantly 
increased the risk of BC (OR=3.70, 95 % 
CI=2.52-5.43, p<0.0001, GA vs GG; 
OR=5.81, 95 % CI=1.53-21.97, p=0.010, AA 
vs GG; OR=2.71, 95 % CI=1.98-3.70, 
p<0.0001, A vs G). In addition, mTOR 
rs2295080 variant significantly increased the 
risk of BC (OR=2.25, 95 % CI=1.50-3.38, 
p<0.0001, GT vs GG; OR=4.75, 95 % 
CI=2.80-8.06, p<0.0001, TT vs GG; 
OR=3.10, 95 % CI=2.34-4.10, p<0.0001, T vs 
G). None of the other examined polymor-
phisms (AKT1 rs1130214, AKT1rs3730358, 
mTOR rs1883965) revealed significant asso-
ciation with BC. 
 
 
Table 3: Genotype and allele frequencies of miRNAs polymorphisms in bladder cancer and controls 
Polymorphism Case n ( %) Control n ( %) OR (95 % CI) p 
PIK3CA rs6443624     
Genotype     
CC 113 (48.1) 73 (28.7) 1.00 - 
CA 111 (47.2) 161 (63.4) 0.44 (0.30-0.65) <0.0001 
AA 11 (4.7) 20 (7.9) 0.35 (0.16-0.78) 0.0107 
Allele     
C 337 (71.7) 307 (60.5)  - 
A 133 (28.3) 201 (39.5) 0.60 (0.46-0.79) 0.0002 
AKT1 rs2498801     
Genotype     
AA 107 (45.5) 82 (32.4) 1.00 - 
AG 124 (52.8) 167 (66.0) 0.57 (0.39-0.82) 0.003 
GG 4 (1.7) 4 (1.6) 0.77(0.19-3.16) 0.731 
Allele     
A 338(71.9) 331 (65.4) 1.00 - 
G 132 (28.1) 175 (34.6) 0.74 (0.56-0.97) 0.032 
AKT1 rs1130233     
Genotype     
GG 94 (40.0) 182 (71.7) 1.00 - 
GA 132 (56.2) 69 (27.2) 3.70 (2.52-5.43) <0.0001 
AA 9 (3.8) 3 (1.2) 5.81 (1.53-21.97) 0.0100 
Allele     
G 320 (68.1) 433 (85.2) 1.00 - 
A 150 (31.9) 75 (14.8) 2.71 (1.98-3.70) <0.0001 
AKT1 rs1130214     
Genotype     
TT 5 (2.1) 10 (3.9) 1.00 - 
TG 225 (97.9) 242 (95.3) 0.54 (0.18-1.59) 0.302 
GG 5 (2.1) 2 (0.8) - - 
Allele     
T 235 (40.0) 262 (51.6) 1.00 - 
G 235 (50.0) 246 (48.4) 0.94 (0.73-1.21) 0.654 
AKT1 rs3730358     
Genotype     
CC 41 (17.5) 34 (13.4) 1.00 - 
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Polymorphism Case n ( %) Control n ( %) OR (95 % CI) p 
CT 185 (78.7) 202 (79.5) 0.76 (0.46-1.25) 0.313 
TT 9 (3.8) 18 (7.1) 0.41 (0.16-1.04) 0.073 
Allele     
C 267 (56.8) 270 (53.1) 1.00 - 
T 203 (43.2) 238 (46.9) 0.86 (0.67-1.11) 0.274 
mTOR rs1883965 
G>A 
    
Genotype     
GG 129 (54.9) 133 (52.4) 1.00 - 
GA 93 (39.6) 110 (43.3) 0.87 (0.60-1.26) 0.512 
AA 13 (5.5) 11 (4.3) 1.22 (0.53-2.82) 0.675 
Allele     
G 351 (74.7) 376 (74.0) 1.00 - 
A 119(25.3) 132 (26.0) 0.97 (0.72-1.29) 0.826 
mTOR rs2295080     
Genotype     
GG 80 (34.0) 152 (59.8) 1.00 - 
GT 90 (38.3) 76 (29.9) 2.25 (1.50-3.38) <0.0001 
TT 65 (27.7) 26 (10.3) 4.75 (2.80-8.06) <0.0001 
Allele     
G 250 (53.2) 380 (77.9) 1.00 - 
T 220 (46.8) 108 (22.1) 3.10 (2.34-4.10) <0.0001 
 
 
 
DISCUSSION 
PI3K, AKT as well as mTOR are proto-on-
cogenes. Genetic variants in PI3K/AKT/ 
mTOR pathway may affect critical cellular 
functions and increase an individual’s cancer 
risk (Mahdi et al., 2015). Mutations of 
PI3K/AKT/mTOR pathways are frequently 
found in cancer, particularly breast cancer 
where about 60 % of tumors harbor genetic 
alterations that hyperactive this signaling 
pathway and was found to be associated with 
cellular transformation, carcinogenesis and 
drug resistance (Engelman, 2009; Guerrero-
Zotano et al., 2016). Mounting evidences pro-
posed that the PI3K/AKT/mTOR pathways 
are generally activated in many cancers in-
cluding bladder cancer, and inhibitors of these 
core genes are displaying great promise as the 
latent anticancer agents (Bellacosa et al., 
2005; Bartholomeusz and Gonzalez-Angulo, 
2012).  
In the present study we investigated the 
impact of PI3K/AKT/mTOR gene polymor-
phisms on bladder cancer risk. The findings 
revealed that PIK3CA rs6443624 C>A and 
AKT1 rs2498801A>G variants caused a sig-
nificant decline in the risk developing bladder 
cancer. The rs1130233 G>A variant of AKT1 
and rs2295080 G>T variant of mTOR signif-
icantly increased the risk of BC. While, we 
detected no significant association between 
AKT1 rs1130214 T>G and rs3730358 C>T 
variants, as well as mTOR rs1883965 G>A 
variant and risk of bladder cancer.  
It has been shown that PIK3CA rs7646409 
variant increased the risk of osteosarcoma in 
the Chinese population (He et al., 2013). Ding 
et al. (2015) proposed that a miR-520a bind-
ing site polymorphism rs141178472 in the 
PIK3CA 3′-untranslated region (3′-UTR) in-
creased the risk of development colorectal 
cancer. Chen et al. (2009) have investigated 
germ line genetic variations in the PI3K-
AKT-mTOR pathway and bladder cancer 
risk. They found that four SNPs (rs11653499 
G>A, rs7211818 A>G, rs7212142 A>G, and 
rs9674559 A>G) in RAPTOR significantly as-
sociated with increased bladder cancer risk. 
While no significant correlation between 
rs12045585 and rs2994329 variants of AKT3 
and bladder cancer risk was observed (Chen 
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et al., 2009). It has been shown that three 
SNPs in PI3K-AKT-mTOR pathway (AKT2 
rs3730050, PIK3R1 rs10515074, and RAP-
TOR rs9906827) were significantly associ-
ated with survival in invasive and metastatic 
bladder cancer patients (Chen et al., 2010). 
Lin et al. (2010) revealed that high caloric in-
take and low physical activity conferred in-
creased bladder cancer risk and that the risk 
may be influenced by genetic variants of 
PI3K/AKT/mTOR pathway genes.  
The expression of PIK3CA was found to 
be increased in human papillary thyroid car-
cinoma (PTC) tissue and microRNA-363-3p, 
as a tumor suppressor gene inhibits PTC pro-
gression by targeting PIK3CA (Liu et al., 
2017). It has been shown that miR-490-5p 
suppresses tumor growth in renal cell carci-
noma by binding to the 3'-UTR of the 
PIK3CA mRNA and reduce the expression of 
PIK3CA at both mRNA and protein levels, 
which further inhibits phosphatidylinositol 3-
kinase/Akt signaling pathway (Chen et al., 
2016). 
Fallah et al. (2015) did not find any sig-
nificant association between AKT1 
rs72715985, rs2494750 and rs74090038 vari-
ants and risk of endometrial cancer in a sam-
ple of Iranian population. Zhu et al. (2016) re-
ported that none of the AKT1 (rs2494750, 
rs2494752 and rs10138277) and AKT2 
(rs7254617 and rs2304186) variants showed 
an association with esophageal squamous cell 
carcinoma (ESCC) risk in an Eastern Chinese 
population. Wang et al. (2016) examined the 
impact of AKT1 rs2494750 G>C, 
rs2494752A >G, rs10138227C >T polymor-
phisms as well as AKT2 rs7254617 G>A and 
rs2304186G >T variants on gastric cancer. 
They found that only AKT1 rs2494752 variant 
significantly increased the risk of gastric can-
cer susceptibility, probable by modulating the 
AKT1 promoter transcriptional activity 
(Wang et al., 2016). It has been shown that 
rs1130214 and rs3803300 variants of AKT1 
significantly increased the risk of OSCC in 
Chinese Han Population (Wang et al., 2015).  
Chen et al. (2012) have found a significant 
association between mTOR rs2295080 as well 
as AKT2 rs7254617 variant and prostate can-
cer (PCa) risk in a Chinese population. It has 
been revealed that AKT/mTOR over-ex-
pressed and PTEN expression was signifi-
cantly decreased in conditions of proliferative 
dysregulation and a variety of solid tumors in-
cluding prostate cancer and gastric cancer 
(Nicholson and Anderson, 2002; Hartmann et 
al., 2009; Riquelme et al., 2016).  
The rs2677764 variant of PIK3CA 
showed a significant association with endo-
metrial cancer (Lacey et al., 2011), while 
other variants of PIK3CA (rs2699905, 
rs7641889, rs7641983, rs7651265, 
rs6443624, rs7640662, rs2677760, 
rs3729692, rs1607237, rs6786049) were not 
associated with the disease. It has been pro-
posed that PI3K signaling pathway is acti-
vated by PIK3CA mRNA over-expression, in 
prostate cancer (Agell et al., 2011).  
Somatic aberrations of PI3K-AKT-
mTOR pathway genes have been generally 
observed in a variety of malignancies. Target-
ing the genetic variations of the 
PI3K/AKT/mTOR pathway has potential use 
in the treatment of various cancer (Vivanco 
and Sawyers, 2002; Carneiro et al., 2015; 
Houede and Pourquier, 2015; Guerrero-
Zotano et al., 2016).  
In summary, the findings of the present 
study provide an association between PI3K-
AKT-mTOR pathway gene polymorphisms 
and risk of developing bladder cancer in a 
sample of Iranian population. Validation of 
the findings in larger sample sizes and differ-
ent ethnicities would provide evidence for the 
role of variants of PI3K/AKT/mTOR path-
way in bladder cancer development. 
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